Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Period	Debt/Equity
2015-12-31	0.12
2016-12-31	0.16
2017-12-31	1.20
2018-12-31	1.07
2019-12-31	1.05
2020-12-31	0.54
2021-12-31	0.51
2022-12-31	0.39
2023-12-31	0.46
2024-12-31	0.44

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NBIX	$131.64	+0.00%	0.82M
3
4
5

Neurocrine Biosciences Inc. (NBIX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Neurocrine Biosciences Inc. Data in Excel

More NBIX Financial Data